Atara biotherapeutics presents key data for advancing the development of tab-cel® and ata188 at the 2021 transplantation & cellular therapy meeting digital experience

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the presentation of data supporting the proposed mechanism of action of their lead product candidate, tabelecleucel (tab-cel®), and five additional poster presentatio
ATRA Ratings Summary
ATRA Quant Ranking